Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
21.43
+0.03 (0.12%)
Mar 27, 2026, 11:22 AM EDT - Market open
DAWN Employees
Day One Biopharmaceuticals had 178 employees as of December 31, 2025. The number of employees decreased by 3 or -1.66% compared to the previous year.
Employees
178
Change
-3
Growth
-1.66%
Revenue / Employee
$888,663
Profits / Employee
-$602,933
Market Cap
2.21B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 178 | -3 | -1.66% |
| Sep 30, 2025 | 184 | 10 | 5.75% |
| Jun 30, 2025 | 182 | 13 | 7.69% |
| Mar 31, 2025 | 181 | 7 | 4.02% |
| Dec 31, 2024 | 181 | 26 | 16.77% |
| Sep 30, 2024 | 174 | 41 | 30.83% |
| Jun 30, 2024 | 169 | 45 | 36.29% |
| Mar 31, 2024 | 174 | 49 | 39.20% |
| Dec 31, 2023 | 155 | 34 | 28.10% |
| Sep 30, 2023 | 133 | 31 | 30.39% |
| Jun 30, 2023 | 124 | 30 | 31.91% |
| Mar 31, 2023 | 125 | 45 | 56.25% |
| Dec 31, 2022 | 121 | 66 | 120.00% |
| Sep 30, 2022 | 102 | 60 | 142.86% |
| Jun 30, 2022 | 94 | 65 | 224.14% |
| Mar 31, 2022 | 80 | 60 | 300.00% |
| Dec 31, 2021 | 55 | 35 | 175.00% |
| Sep 30, 2021 | 42 | 22 | 110.00% |
| Jun 30, 2021 | 29 | - | - |
| Mar 31, 2021 | 20 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Apellis Pharmaceuticals | 739 |
| Adaptive Biotechnologies | 624 |
| Syndax Pharmaceuticals | 298 |
| Celldex Therapeutics | 198 |
| Immunome | 177 |
| Disc Medicine | 155 |
| Kodiak Sciences | 123 |
DAWN News
- 17 days ago - Are DAWN and TALK Obtaining Fair Deals for their Shareholders? - PRNewsWire
- 20 days ago - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN) - Newsfile Corp
- 20 days ago - Is there any upside left in DAWN stock as it soars 65%? - Invezz
- 21 days ago - Day One Shares Surge After $2.5B Servier Deal - Benzinga
- 21 days ago - Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion - Reuters
- 21 days ago - Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio - GlobeNewsWire
- 21 days ago - Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth - Seeking Alpha
- 27 days ago - Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead - Seeking Alpha